These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 662717)

  • 41. Single versus combination chemotherapy of L1210 leukemia.
    Koza I; Balázová E; Ujházy V
    Neoplasma; 1980; 27(6):691-6. PubMed ID: 7254424
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potentially useful combinations of chemotherapy detected in mouse tumor systems.
    Kline I
    Cancer Chemother Rep 2; 1974 Mar; 4(1):33-43. PubMed ID: 4133187
    [No Abstract]   [Full Text] [Related]  

  • 43. R17934-NSC238159: a new antitumor drug--II. Effect on mitotic cycle of L1210 leukemia cells in vivo and synergism with cytosine arabinoside (NSC63878).
    Atassi G; Schaus C; Tagnon HJ
    Eur J Cancer (1965); 1975 Sep; 11(9):609-14. PubMed ID: 1220976
    [No Abstract]   [Full Text] [Related]  

  • 44. Basis of observed resistance of L1210 leukemia in mice: methotrexate, 6-thioguanine, 6-methylmercaptopurine riboside, 6-mercaptopurine, 5-fluorouracil, and 1-beta-D-arabinofuranosylcytosine administered in different combinations.
    Kim K; Blechman WJ; Riddle VG; Pardee AB
    Cancer Res; 1981 Nov; 41(11 Pt 1):4529-34. PubMed ID: 7198006
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
    [No Abstract]   [Full Text] [Related]  

  • 46. The chemotherapy of human and animal acute leukemia.
    Goldin A; Sandberg JS; Henderson ES; Newman JW; Frei E; Holland JF
    Cancer Chemother Rep; 1971 Nov; 55(4):309-505. PubMed ID: 4945857
    [No Abstract]   [Full Text] [Related]  

  • 47. Neoplasia, kinetics, nd chemotherapy.
    Hart JS; Livingston RB; Murphy WK; Barlogie B; Gehan EA; Bodey GP
    Semin Oncol; 1976 Sep; 3(3):259-70. PubMed ID: 790580
    [No Abstract]   [Full Text] [Related]  

  • 48. Cytotoxicity of methylglyoxal bis(guanylhydrazone) in combination with alpha-difluoromethylornithine against HeLa cells and mouse L1210 leukemia.
    Sunkara PS; Prakash NJ; Chang CC; Sjoerdsma A
    J Natl Cancer Inst; 1983 Mar; 70(3):505-9. PubMed ID: 6403743
    [No Abstract]   [Full Text] [Related]  

  • 49. Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
    Frei E; Schabel FM; Goldin A
    Cancer Res; 1974 Jan; 34(1):184-93. PubMed ID: 4520419
    [No Abstract]   [Full Text] [Related]  

  • 50. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. IX.
    Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
    Cancer Chemother Rep 2; 1971 Apr; 2(1):65-133. PubMed ID: 5565539
    [No Abstract]   [Full Text] [Related]  

  • 51. [Potentiation of the antitumor action of alkylating compounds by amphotericin B].
    Iaremenko KV; Eremeeva AA; Tereshin IM
    Antibiotiki; 1977; 22(2):153-8. PubMed ID: 404957
    [No Abstract]   [Full Text] [Related]  

  • 52. Effectiveness of antitumor agents administered subcutaneously to L1210 leukemic mice in silicone rubber devices.
    Neil GL; Scheidt LG; Kuentzel SL; Moxley TE
    Chemotherapy; 1973; 18(1):27-40. PubMed ID: 4681847
    [No Abstract]   [Full Text] [Related]  

  • 53. [Cancerostatic effect of some fluorenone azomethines tested against leukemia L 1210 (author's transl)].
    Jungstand W; Gutsche W; Wohlrabe K; Schulze W
    Arch Geschwulstforsch; 1979; 49(1):15-7. PubMed ID: 444028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Commentary. The role of structure-activity studies in the design of antitumor agents.
    Cain BF
    Cancer Chemother Rep; 1975; 59(4):679-83. PubMed ID: 1175161
    [No Abstract]   [Full Text] [Related]  

  • 55. Therapeutic performance of carminomycin-cyclophosphamide against L1210 leukemia.
    Avery TL; Cruze PG
    Cancer Res; 1978 Sep; 38(9):2892-5. PubMed ID: 679196
    [No Abstract]   [Full Text] [Related]  

  • 56. Experimental antitumor activity of 5'-nor-anhydrovinblastine navelbine.
    Maral R; Bourut C; Chenu E; Mathé G
    Cancer Lett; 1984 Feb; 22(1):49-54. PubMed ID: 6697321
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
    [No Abstract]   [Full Text] [Related]  

  • 58. Drug resistance induction and cross-resistance studies with Pt-complexes.
    Hrubisko M; Balázová E; Ujházy V
    Neoplasma; 1984; 31(6):649-53. PubMed ID: 6542968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spleen colony studies of leukemia L1210. IV. Sensitivities of L1210 and L1210/6-MP to triazenoimidazolecarboxamides--a preliminary report.
    Wodinsky I; Swiniarski J; Kensler CJ
    Cancer Chemother Rep; 1968 Apr; 52(3):393-8. PubMed ID: 5670721
    [No Abstract]   [Full Text] [Related]  

  • 60. Increased lifespan using the priming dose schedule design in carbazilquinone (NSC-134679) treatment of mouse leukemia L1210.
    Straus MJ; Goldin A
    Cancer Chemother Rep; 1972 Feb; 56(1):19-23. PubMed ID: 5030804
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.